January 31, 2024 - … General Company to reprioritize resources allocated to ADUHELM ® (aducanumab-avwa) to advance LEQEMBI ® … will discontinue the development and commercialization of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for … the resources released resulting from termination of the ADUHELM program will be redeployed in Biogen’s AD franchise. …